Probi AB (publ)
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $17.75
- Today's High:
- $17.75
- Open Price:
- $17.75
- 52W Low:
- $16.76
- 52W High:
- $18.9
- Prev. Close:
- $16.76
- Volume:
- 200
Company Statistics
- Market Cap.:
- $206.07 million
- Book Value:
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $255.45 million
- Profit Margin:
- 3.25%
- Return on Assets TTM:
- 0.77%
- Return on Equity TTM:
- 1.39%
Company Profile
Probi AB (publ) had its IPO on under the ticker symbol PBBIF.
The company operates in the sector and industry. Probi AB (publ) has a staff strength of 164 employees.
Stock update
Shares of Probi AB (publ) opened at $17.75 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $17.75 - $17.75, and closed at $17.75.
This is a +5.91% increase from the previous day's closing price.
A total volume of 200 shares were traded at the close of the day’s session.
In the last one week, shares of Probi AB (publ) have increased by +5.91%.
Probi AB (publ)'s Key Ratios
Probi AB (publ) has a market cap of $206.07 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Probi AB (publ)’s revenue was $0 with a gross profit of $255.45 million and an EBITDA of $0. The EBITDA ratio measures Probi AB (publ)'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Probi AB (publ)’s operating margin was 0% while its return on assets stood at 0.77% with a return of equity of 1.39%.
In Q3, Probi AB (publ)’s quarterly earnings growth was a positive 37.5% while revenue growth was a negative 17.6%.
Probi AB (publ)’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Probi AB (publ)’s profitability.
Probi AB (publ) stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Probi AB (publ) stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0
- Total Liabilities
- $73.18 million
- Operating Cash Flow
- $-14071000.00
- Capital Expenditure
- $10.54 million
- Dividend Payout Ratio
- 0%
Probi AB (publ) ended 2024 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.
Probi AB (publ) ended 2024 with $26.45 million in deferred long-term liabilities, $73.18 million in other current liabilities, 58221000.00 in common stock, $616.96 million in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Probi AB (publ)’s total current assets stands at $544.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $96.70 million compared to accounts payable of $28.73 million and inventory worth $111.48 million.
In 2024, Probi AB (publ)'s operating cash flow was $-14071000.00 while its capital expenditure stood at $10.54 million.
Comparatively, Probi AB (publ) paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $17.75
- 52-Week High
- $18.9
- 52-Week Low
- $16.76
- Analyst Target Price
- $
Probi AB (publ) stock is currently trading at $17.75 per share. It touched a 52-week high of $18.9 and a 52-week low of $18.9. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $17.25 and 200-day moving average was $33.77 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7185.4% of the company’s stock are held by insiders while 1983.4% are held by institutions.
Frequently Asked Questions About Probi AB (publ)
Most Active
Top Gainers
Top Losers
About
Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, the Middle East, Africa, Asia, and Pacific. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children’s, women’s, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; University of Gothenburg to investigate the effects of probiotic strain LP299V on iron absorption; Wageningen University & Research to understand the molecular interactions occurring between microbes and its hosts; University of Umeå to investigate the effects of the strain LP299V on iron status in female athletes; and University of Aberdeen to characterize bacterial isolates with next generation probiotics. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.